21 recruiting, 13 active not recruiting, 13 completed, 9 unknown. 39 Phase 2, 30 Phase 1, 5 Phase 3, 3 Early Phase 1.
Follow DLBCL: new trials by email Literature Review of DLBCL trials Research Report on DLBCL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pirtobrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL pirtobrutinib combined with BEAM - DLBCL | Phase 2 | Not yet recruiting | Ruijin Hospital | 28 | 2026-08-25 | 2026-08-19 |
| A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Rocbrutinib, R-GemOx - DLBCL | Phase 1 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 42 | 2026-06-25 | 2026-09-10 |
| Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL EZH2i+GLofit-GemOx - DLBCL | Phase 1 / Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 46 | 2026-06-01 | 2026-06-12 |
| Gut Microbiome in DLBCL Treated With Glofitamab Gut microbiome analysis - DLBCL, Glofitamab | Not yet recruiting | Peking Union Medical College Hospital | 30 | 2026-04-01 | 2026-03-27 | |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| Evaluating the Treatment Outcomes of Tafasitamab in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma: a Real-world Evidence Study Minjuvi - DLBCL | Active not recruiting | TTY Biopharm | 50 | 2025-12-01 | 2026-07-16 | |
| Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma BAFF-R CAR-T - DLBCL, CLL | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-11-29 | 2026-05-13 |
| Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma EBV TCR-T - NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL) | Early Phase 1 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 24 | 2025-09-20 | 2025-12-02 |
| Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET POLA-R-CHP - Diffuse Large B-Cell Lymphoma, DLBCL | Recruiting | Fudan University | 300 | 2025-05-09 | 2025-07-17 | |
| Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy Drug therapy - DLBCL, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | First Affiliated Hospital of Ningbo University | 50 | 2025-01-15 | 2025-03-18 |
| A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL Low intensity treatment options, Conventional immunochemotherapy regimen - DLBCL | Recruiting | Ruijin Hospital | 400 | 2025-01-01 | 2025-02-19 | |
| CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) CDR-CHOP - DLBCL | Phase 2 | Not yet recruiting | Ruijin Hospital | 34 | 2024-12-31 | 2024-12-27 |
| CR-CHOP+X in Previously Untreated DEL CR-CHOP+PD1 inhibitor, CR-CHOP + Orelabrutinib, CR-CHOP + decitabine - DLBCL | Phase 2 | Recruiting | Ruijin Hospital | 49 | 2024-12-10 | 2024-12-30 |
| Zanubrutinib Combined With BEAM for ASCT in Relapsed and Refractory DLBCL zanubrutinib combined with BEAM, BEAM - DLBCL | Phase 2 | Not yet recruiting | Ruijin Hospital | 66 | 2024-11-01 | 2024-10-22 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma DLBCL | Recruiting | The Clatterbridge Cancer Centre NHS Foundation Trust | 800 | 2024-10-30 | 2026-01-12 | |
| A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Diffuse Large B-Cell Lymphoma Patients Trilaciclib+R-CHOP - DLBCL | Phase 2 | Recruiting | Sun Yat-sen University | 38 | 2024-05-23 | 2024-08-26 |
| Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Tafasitamab, Lenalidomide, Gemcitabine - DLBCL | Phase 3 | Recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | 244 | 2024-05-07 | 2024-07-25 |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies P-CD19CD20-ALLO1, Rimiducid - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High-grade B-cell Lymphoma | Phase 1 | Active not recruiting | Poseida Therapeutics, Inc. | 120 | 2024-04-16 | 2026-05-07 |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
Showing 20 of 74. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (18) · Lymphoma, Non-Hodgkin (12) · Lymphoma, Follicular (11) · Lymphoma, B-Cell, Marginal Zone (8) · Lymphoma, Mantle-Cell (7) · Lymphoma (6) · Recurrence (6) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, B-Cell (4) · Waldenstrom Macroglobulinemia (4) · Dendritic Cell Sarcoma, Interdigitating (3) · Multiple Myeloma (3) · Pyloric Stenosis, Hypertrophic (3) · Breast Neoplasms (2) · Burkitt Lymphoma (2)
Hemic and Lymphatic Diseases (36) · Immune System Diseases (36) · Immunoproliferative Disorders (36) · Lymphatic Diseases (36) · Lymphoproliferative Disorders (36) · Neoplasms by Histologic Type (36) · Neoplasms (34) · Lymphoma (30) · Lymphoma, B-Cell (22) · Lymphoma, Non-Hodgkin (22) · Pathologic Processes (13) · Pathological Conditions, Signs and Symptoms (13) · Disease Attributes (10) · Hematologic Diseases (8) · Blood Protein Disorders (7)
Rituximab (14) · Cyclophosphamide (10) · Doxorubicin (7) · Prednisone (7) · Vincristine (6) · Lenalidomide (5) · tafasitamab (4) · Gemcitabine (3) · acalabrutinib (3) · fludarabine (3) · Bendamustine Hydrochloride (2) · Etoposide (2) · Oxaliplatin (2) · orelabrutinib (2) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1)
Ruijin Hospital (6) · Sun Yat-sen University (4) · The Lymphoma Academic Research Organisation (4) · Acerta Pharma BV (2) · Beijing InnoCare Pharma Tech Co., Ltd. (2) · Memorial Sloan Kettering Cancer Center (2) · Merck Sharp & Dohme LLC (2) · Rennes University Hospital (2) · Stichting Hemato-Oncologie voor Volwassenen Nederland (2) · The First Affiliated Hospital with Nanjing Medical University (2) · University of Rochester (2) · Acepodia Biotech, Inc. (1) · Autolus Limited (1) · Bio-Path Holdings, Inc. (1) · Chinese Academy of Medical Sciences (1)
United States (30) · China (19) · France (12) · Italy (9) · United Kingdom (7) · Spain (6) · Australia (5) · Belgium (5) · Poland (5) · South Korea (5) · Netherlands (4) · Denmark (3) · Germany (3) · Ukraine (3) · Canada (2)
Annkristin Heine, MD (1) · Ashwin Gollerkeri, MD (1) · Carla Casulo (1) · Christopher Fletcher, MD (1) · Christopher J Melani, M.D. (1) · Dmitrij Kravchenko, MD (1) · Emmanuelle Tchernonog (1) · Franck Morshhauser, Pr (1) · Frank G Basile, M.D. (1) · Gilles Salles (1) · Huiqiang Huang, professor (1)
PMID 18042692, PMID 19880495, PMID 20671118, PMID 23023715, PMID 23649469, PMID 24142051, PMID 26202875, PMID 26222726, PMID 26353084, PMID 26424652, PMID 27269947, PMID 28903943, PMID 28911074, PMID 29920566, PMID 30446007, PMID 31724191, PMID 32122924, PMID 32299513, PMID 33242451, PMID 33512414, PMID 33750072, PMID 34269152, PMID 34508654, PMID 35538512, PMID 36548927, PMID 37399456, PMID 37781191, PMID 38022532, PMID 38151388, PMID 38889737, PMID 38996463, PMID 39322711, PMID 40249860, PMID 40472301, PMID 40802906, PMID 41176775, PMID 41260259, PMID 42411504, PMID 42431612, PMID 42541678
2017 (3), 2015 (1), 2016 (1), 2023 (1), K08CA248968 (1)